![]() |
市场调查报告书
商品编码
1218882
全球眼科激光市场:到 2028 年的预测——按产品、应用、最终用户和地区分析Ophthalmic Lasers Market Forecasts to 2028 - Global Analysis By Product, Application, End User and By Geography |
根据 Stratistics MRC 的数据,2022 年全球眼科激光市场规模将达到 13.7507 亿美元,预计到 2028 年将达到 20.2914 亿美元,预测期内復合年增长率为 6.7%。眼科激光是能够精确治疗各种眼部问题且几乎没有感染风险的工具。许多激光手术可以在没有麻醉的情况下进行,而且疼痛很小。眼科激光由于其安全性、准确性和相对经济性的结合而成为眼科领域特别有用的仪器。激光控制台、脚踏板和激光传输系统是激光系统的三大要素。可以使用通过光纤电缆连接到控制台的各种传输设备将激光能量传输到患者的眼睛。
研究发现,女性在儿童时期患近视的可能性比男性高 24%,但成年后患近视的可能性低 12%。其原因不明,但可能是由于荷尔蒙的变化和男女生活方式的差异。
市场动态
促进者
眼科疾病的患病率
屈光不正、年龄相关性黄斑变性、白内障、糖尿病性视网膜病变和青光眼等眼科疾病的全球患病率上升是推动眼科激光市场增长的关键因素之一。此外,眼科微创手术和技术创新的趋势推动了眼科激光设备市场的需求。此外,保持适当眼睛健康的需求不断增加,这将推动全球眼科激光市场的增长。
抑製剂
替代疗法的可用性
视力矫正替代疗法的可用性预计将阻碍眼科医用激光市场。眼科学中的激光替代疗法包括使用晶状体进行视力矫正,使用诸如有晶状体眼人工晶状体植入物和屈光晶状体置换手术等技术。美国白内障和屈光手术学会 (ASCRS) 的统计数据证实,选择标准人工晶状体手术(白内障手术被认为是安全的)的患者可以完全恢復视力。因此,视力矫正替代疗法的可用性预计会阻碍眼科医用激光市场。
机会
眼科激光治疗眼病的效率
年龄相关性青光眼、白内障、近视和其他眼病影响着许多患者,尤其是老年人。药物治疗对某些眼病的疗效一般,这就是眼科激光等治疗眼病的医疗器械市场不断增长的原因。世界卫生组织估计,全世界有 1800 万人因白内障而双眼失明。此外,近视、极度近视、老花眼等屈光问题患者较多,市场机会广阔。
威胁
成本高
由于医务人员监管不力,发生了很多不幸事件,这削弱了用户的信任。例如,直视强光引起的事故可能导致不可逆的眼睛损伤以及部分或完全失明。如果激光束击中未受保护的眼睛,也会造成伤害。同样,有一份名单列出了那些经常不愿接受这种待遇的人,这些人共同代表了相当大一部分潜在客户并阻碍了市场增长。
COVID-19 的影响
COVID-19 的爆发对眼科激光市场产生了相反的影响。在大流行期间,主要的医疗保健治疗已被推迟,以减少冠状病毒传播的机会。在大流行期间,主要的健康治疗已被推迟,以减少冠状病毒传播的机会。然而,由于 COVID 后放鬆管制,预计眼保健会有所增加。这些障碍正在影响眼科激光市场的增长。
飞秒激光细分市场预计将在预测期内成为最大的细分市场
飞秒激光部分估计有良好的增长;飞秒激光因为其极短的脉衝持续时间和红外激光。由于脉衝持续时间短,飞秒激光器可以传送激光能量,对周围组织几乎没有附带伤害。飞秒激光的优势还在于它们可以照射角膜内部或下方的任何地方,并且可以部分穿过光学混浊介质,例如水肿角膜。支持市场增长。
白内障切除部分预计在预测期内表现出最高的复合年增长率
由于易于切割和晶状体开口的激光碎裂,预计白内障切除术在预测期内将呈现最快的复合年增长率。与手工操作相比,此过程可产生更可靠、可重复和精确的切口。即使是熟练的外科医生也无法製作出与激光相同精度的完美圆形开口。医生之所以能够这样做,是因为激光可以进行精确可靠的切口,从而带来更好、更可预测的视觉效果。因此,上述所有因素都在推动市场增长。
市场占有率最高的地区
由于研发部门的发展、医疗改革的加强以及眼科领域的科学发展,亚太地区预计在预测期内将占据最大的市场份额。亚太地区眼科激光市场的扩张主要是由于医疗保健基础设施的改善以及配备最先进设备的医院数量的增加。此外,眼科激光系统的技术进步和眼科诊断设备市场的扩大将进一步推动眼科激光製造商的市场增长。
复合年增长率最高的地区
欧洲在全球眼科激光器市场中占有很大份额,预计在预测期内将保持这一主导地位,因此欧洲将成为预测期内復合年增长率最高的地区。其背景是眼科疾病患者数量的增加、对患者安全设备的需求增加、配备熟练医务人员的最先进医疗设施的可用性以及研发活动的数量随着重要公司的出现,政府对医疗保健系统的投资有所增加,从而推动了市场的增长。
重大发展
2022年12月,Novartis宣布将向绝经前和绝经后激素受体阳性、人类表皮生长因子受体2阴性(HR+/HER2?)晚期转移性乳腺癌(MBC)患者,包括伴有内臟危象的患者率先宣布- Quiscari (R) (ribociclib) 联合内分泌治疗 (CT) 的 RIGHT 选择 II 期试验的结果。
2022 年 12 月,Novartis宣布 Pluvicto □( INN :橹(177Lu)vipivotide tetraxetan)是一种靶向前列腺特异性膜抗原( PSMA )的放射配体治疗药物,在其关键的第三阶段研究中达到了主要终点, PSMAfore 宣布。
2022 年 12 月,Johnson & Johnson Vision 宣布在新加坡推出用于近视管理的 ACUVUE(R) Ability(TM) 1 天软性治疗镜片,开始治疗时 7 岁的每日佩戴一次性镜片可能会减缓 12 岁以上儿童的近视进展岁。
2022年11月,Bosh Health宣布根据Bosh Health条款不受限制地使用Bausch + Lomb。因此,1261229 BC Ltd. 的所有子公司,包括 Bausch + Lomb 及其子公司,也已成为本公司的非限制性子公司,因此不再受 Bosch Health 债务文件项下契约的约束。
本报告内容
免费定制服务
订阅此报告的客户将免费获得以下自定义选项之一。
According to Stratistics MRC, the Global Ophthalmic Lasers Market is accounted for $1375.07 million in 2022 and is expected to reach $2029.14 million by 2028 growing at a CAGR of 6.7% during the forecast period. Ophthalmic lasers are tools that enable precision therapy for a variety of eye issues with little danger of infection. Numerous laser operations can be done without anaesthesia and with little to no pain. Ophthalmic lasers are a particularly helpful instrument in the field of ophthalmology due to its combination of safety, accuracy, and relative affordability. The laser console, the foot pedal, and the laser delivery system are the three main elements of a laser system. The laser energy can be delivered to the patient's eye using a variety of delivery devices that are linked to the console by a fibre optic cable.
According to the study, women were 24% more likely than men to develop myopia as children, but they were 12% less likely to do so as adults. It's unclear why this is the case, but it could be because men and women endure different hormonal shifts or different lifestyles.
Market Dynamics:
Driver:
Prevalence of Ophthalmic Disorders
The rise in prevalence of ophthalmic disorders such as refractive errors, age-related macular degeneration, cataract, diabetic retinopathy and glaucoma, among others across the globe, is one of the major factors driving the growth of ophthalmic lasers market. Moreover, inclination towards minimally invasive procedures and innovations in ophthalmic will propel the demand in ophthalmic laser machines market. Further, growing need for maintaining proper eye health will drive growth in the global ophthalmic lasers market.
Restraint:
Availability of Alternative Therapies
The availability of alternative therapies for vision correction is expected to hinder the ophthalmic medical lasers market. The alternatives for lasers in ophthalmology include using a lens for correcting the vision using techniques such as Phakic Intraocular Lens Implants, and Refractive Lens Exchange Surgery. According to the statistics by the American Society of Cataract and Refractive Surgery (ASCRS), patients who choose to have a standard IOL procedure, which is considered safe for cataract surgery, experience fully restored vision. Therefore, the availability of alternative therapies to correct vision is expected to hamper the ophthalmic medical lasers market.
Opportunity:
Efficiency of ophthalmic lasers in the treatment of ocular diseases
Age-related glaucoma, cataract, myopia, and other eye illnesses affect a considerable patient base, particularly the older population. Because medications are only moderately effective in treating certain eye conditions, there is a growing market for medical devices, such as ophthalmic lasers, to treat eye conditions. The world health organization estimates that 18 million people worldwide are blind on both sides as a result of cataract. Additionally, a significant patient population experiences refractive problems like myopia, extreme myopia, and presbyopia which are providing wide range of opportunities to the market.
Threat:
High Cost
Numerous unfortunate circumstances caused by the poor supervision of medical professionals have occurred, undermining user confidence. For instance, accidents brought on by looking steadily into the light might irreversibly harm the eye and cause partial or complete blindness. Additionally, when a laser beam is projected into somebody's unprotected eyes, damage can result. Likewise, there is a list of persons who are frequently discouraged from receiving such therapies taken as a whole they represent a sizable portion of potential clients hindering the market growth.
COVID-19 Impact
The COVID-19 outbreak had a contradictory effect on the market for ophthalmic lasers. Significant healthcare treatments were postponed during the pandemic to decrease the likelihood of corona virus transmission. Major health treatments were postponed during the pandemic to reduce the chance of corona virus transmission. However, due to the easing of regulations after COVID, an increase in ophthalmic treatments is anticipated. Such hindrances are affecting the growth of the ophthalmic lasers market.
The femtosecond lasers segment is expected to be the largest during the forecast period
The femtosecond lasers segment is estimated to have a lucrative growth; due to their infrared laser with incredibly little pulse duration is the femtosecond laser. The femtosecond laser can deliver laser energy with little collateral harm to the surrounding tissue because of its brief pulse duration. The femtosecond laser is also exceptional in that it may be directed anywhere inside or below the cornea and can partially pass through optically cloudy media, like an edematous cornea which are boosting the market growth.
The cataract removal segment is expected to have the highest CAGR during the forecast period
The cataract removal segment is anticipated to witness the fastest CAGR growth during the forecast period, due to its ease on making incision and lens opening are made fragmented using a laser. This procedure produces a more dependable, reproducible, and exact incision than can be achieved by hand. Even a skilled surgeon cannot create a perfectly round aperture with the same level of precision as a laser. Doctors can do that because of the laser's accuracy and reliability in making incisions which leads to a better and more predictable vision outcome. Therefore, all the above factors are driving the market growth.
Region with highest share:
Asia Pacific is projected to hold the largest market share during the forecast period owing to the development of the R&D sector, an increase in healthcare reforms, and scientific developments in the field of ophthalmology. Asia-Pacific ophthalmic lasers market, primarily as a result of improvements in the healthcare infrastructure, an increase in the number of hospitals with cutting-edge equipment. Furthermore, technological advancements in ophthalmic laser systems and expansion of ophthalmic diagnostic equipment market will further aid ophthalmic laser manufacturers to increase the growth of the market
Region with highest CAGR:
Europe is projected to have the highest CAGR over the forecast period, owing to a substantial share of the worldwide market for ophthalmic lasers, and it is anticipated that it will continue to hold this dominance during the forecast period. This is attributed to a rise in the number of ophthalmic disabilities, an increase in the demand for patient safety devices, the accessibility of cutting-edge healthcare facilities with skilled healthcare workers, an increase in the number of Research and development activities along with a notable presence of crucial players, and an increase in government investment in the healthcare system thereby propelling the market growth.
Key players in the market
Some of the key players profiled in the Ophthalmic Lasers Market include Novartis AG , Bausch Health Companies Inc, Topcon Corporation, Johnson & Johnson Surgical Vision Inc, IRIDEX Corporation, Ziemer Opthalmic Systems AG, LIGHTMED, SCHWIND eye-tech-solutions, Lumenis, Lumibird Group, Carl Zeiss Meditec AG, NIDEK Co., Ltd, Abbott Medical Optics Inc and Alcon Inc.
Key Developments:
In Dec 2022, Novartis announced results from the RIGHT Choice Phase II trial evaluating Kisqali® (ribociclib) plus endocrine therapy (ET) against combination chemotherapy (CT) in the first-line setting for pre- and perimenopausal patients with aggressive forms of hormone receptor-positive, human epidermal growth factor receptor-2 negative (HR+/HER2?) metastatic breast cancer (MBC), including patients with visceral crisis.
In Dec 2022, Novartis announced the pivotal Phase III PSMAfore study with PluvictoTM (INN: lutetium (177Lu) vipivotide tetraxetan), a prostate-specific membrane antigen (PSMA)-targeted radioligand therapy, met its primary endpoint.
In Dec 2022, Johnson & Johnson Vision Announces Availability of ACUVUE® Abiliti™ 1-Day Soft Therapeutic Lenses for Myopia Management in Singapore, the daily wear, single-use, disposable lens has the potential to slow the progression of myopia in children who are 7 to 12 years old at the start of treatment.
In Nov 2022, Bausch Health Announces the Unrestricting of Bausch + Lomb Under Bausch Health Debt Covenants. In connection therewith, all of the subsidiaries of 1261229 B.C. Ltd., including Bausch + Lomb and its subsidiaries, are also now unrestricted subsidiaries of the Company and, as a result, are no longer subject to the covenants under the Bausch Health debt documents.
Products Covered:
Applications Covered:
End Users Covered:
Regions Covered:
What our report offers:
Free Customization Offerings:
All the customers of this report will be entitled to receive one of the following free customization options: